What’s surprising is how little force is required in some of these femur fractures—just standing up can be enough,” said Spangenberg Fosamax attorney William Eadie.
Cleveland, OH (PRWEB) May 05, 2011
Recent medical research has linked Fosamax®, a prescription drug used to treat osteoporosis in both men and women, with weakened bones that can lead to spontaneous, low-force bone breaks (1). The Spangenberg law firm is investigating potential lawsuits on behalf of current or former Fosamax users who have suffered from these unusual (or “atypical”) bone fractures.
Femoral fractures can be devastating injuries, as the femur (or thigh bone) is a vital bone that rarely breaks absent more serious impact trauma like a car accident. To break the thighbone across its length (shaft)—the type of femur fracture typically associated with Fosamax use—usually takes an even greater amount of force (2). Symptoms of a femoral fracture include severe pain, inability to move the leg, deformity, and swelling. Open fractures have added potential for infection. Activities that might result in a Fosamax-related femur fracture include walking down steps, sitting or standing, and walking. This past March, Fosamax’s pharmaceutical manufacturer, Merck, asked the Judicial Panel on Multidistrict Litigation (MDL) to combine existing Fosamax femur fracture lawsuits into a single proceeding. (MDL No. 2243In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II).) Merck requested the Panel send the case to the U.S. District Court for the District of New Jersey before District Court Judge Garrett Brown. Merck is located in this district. Some plaintiffs are resisting this effort.
The FDA has reported on the alarming incidences of femur fractures for long-term Fosamax users. The Spangenberg law firm has provided information on potential Fosamax lawsuits at http://www.my-fosamax-lawsuit.com. The website provides information on Fosamax femur fractures and other possibly Fosamax-related injuries. The Spangenberg law firm can also be reached at 1-877-696-3303.
Patients suffering from this type of injury after taking Fosamax should consult with a Fosamax injury attorney soon to evaluate whether they have a Fosamax-related potential legal claim. There may be a statute of limitations clock running, which limits the time period in which you can file a lawsuit.
Other potential Fosamax-related injuries include:
- Esophageal Cancer(3). A recent study, published by the British Medical Journal, indicates that long-term users of Fosamax may face a double risk of esophageal (throat) cancer. Esophageal cancer is cancer that occurs in the esophagus--the tube that runs from the throat to the stomach. Patients in the study who took the drug were exposed to throat cancer at an approximate rate of 2-in-1,000, versus the standard risk of 1-in-1,000.
- Jawbone Fosamax Injuries (4). Osteonecrosis of the jaw (ONJ), also referred to as “Dead Jaw,” is a type of bone disease that is linked to a temporary or permanent blood restriction to the affected bone(s) which results in death of bone tissue and an eventual collapse of the bone. ONJ-Fosamax injuries may begin with pain or numbness in the jaw region, and then progress to a loosening of the teeth, frequent infection of the area, and degradation of the jawbone.
- Heart Condition Fosamax Injuries (Atrial Fibrillation) (5). Use of Fosamax may also double women’s risk of developing the chronic heart condition known as atrial fibrillation, which causes a recurring irregular heartbeat. A recent report found that women taking Fosamax were at a higher risk of developing atrial fibrillation than those not on Fosamax.
Spangenberg attorneys are willing to provide no-cost, confidential case reviews for Fosamax patients who have had any of these injuries. You can reach a Spangenberg Fosamax-injury attorney at http://www.my-fosamax-lawsuit.com/contact or by calling 1-877-696-3303 (toll-free). Spangenberg Shibley & Liber is a law firm with a national dangerous drugs practice headquartered in Ohio.
FOSAMAX® is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. No ownership of this trademark is claimed or implied by this article.
(1) N Engl J Med 2011;364:1728-37
(3) BMJ 2010;341:c4444